
Repeated injections of onabotulinumtoxinA (onabotA [Botox]), 100 U, continue to provide benefit in patients with overactive bladder syndrome and urinary incontinence and without any new safety concerns, according to results of a pre-specified interim analysis in an open-label, 3-year extension study.
